R Squared’s Exagen XGN Stock Holding History

R Squared’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$121K	Sell	26,073 -1,034	-4%	-$3.89K	0.06%	388
2026 Q1	$81.3K	Buy	27,107 +8,915	+49%	+$34.5K	0.04%	384
2025 Q4	$111K	Buy	+18,192	New	+$166K	0.05%	402

Other funds holding XGN

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

MBAM

Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

R Squared's XGN Position: Q2 2026 in Review

R Squared reduced its Exagen (XGN) stake by 3.8% in Q2 2026, selling an estimated $3.89K and leaving 26,073 shares worth $121K. The position accounts for 0.06% of the portfolio, ranked #388.

R Squared first reported a position in XGN in Q4 2025 and has held it in 3 quarters since. 57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

R Squared held 26,073 shares of Exagen worth $121K as of Q2 2026.
R Squared sold 1,034 Exagen shares in Q2 2026, an estimated $3.89K.
Exagen made up 0.06% of R Squared's portfolio in Q2 2026, its #388 holding.
R Squared first reported a position in Exagen in Q4 2025 and has held it in 3 quarters since.
57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.